NMRA 주가 차트
NMRA 재무
Neumora Therapeutics Inc
$1.53
-1.92%
$-0.03
종가: Jun 17, 16:00:00 GMT-4
$1.51
-1.29%
$-0.01
프리마켓: Jun 18, 05:58:46 GMT-4
뒤로
Neumora Therapeutics Inc (NMRA) 재무
주요 통계
이전 종가
$1.56
시가
$1.46
일일 범위
$1.32 - $1.54
52주 범위
$0.6581 - $3.65
거래량
5.3M
평균 거래량
1.3M
배당수익률
--
EPS(TTM)
-1.33
시가총액
$279.8M
NMRA란 무엇인가요?
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Watertown, Massachusetts and currently employs 96 full-time employees. The company went IPO on 2023-09-15. The firm's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The firm's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
